Target Name: FCHSD1
NCBI ID: G89848
Review Report on FCHSD1 Target / Biomarker Content of Review Report on FCHSD1 Target / Biomarker
FCHSD1
Other Name(s): protein nervous wreck 2 | Nervous wreck homolog 2 | Protein nervous wreck 2 | F-BAR and double SH3 domains protein 1 | FLJ00007 | nervous wreck homolog 2 | FCH and double SH3 domains protein 1 | NWK2 | FCSD1_HUMAN | FCH and double SH3 domains 1

FCHSD1: The Protein Nervous Wreck 2 and Its Potential as a Drug Target

Introduction

FCHSD1, or protein nervous wreck 2, is a protein that is expressed in various tissues of the brain, including the nervous system. Its function and structure have been studied extensively in recent years, and its potential as a drug target or biomarker continues to gain traction. In this article, we will provide an overview of FCHSD1, its structure, function, and potential as a drug target.

Structure and Function

FCHSD1 is a protein that is composed of 115 amino acid residues and has a calculated molecular weight of 13.9 kDa. It is expressed in various tissues of the brain, including the nervous system, and is involved in the development and maintenance of the nervous system.

One of the defining features of FCHSD1 is its unique structure. FCHSD1 is a type of transmembrane protein that consists of a single transmembrane domain and a cytoplasmic tail. The transmembrane domain is characterized by the presence of a long terminal coiled region (CTR) and a short cytoplasmic region (CCR). The CTR is responsible for the protein's ability to interact with other proteins and molecules, while the CCR is involved in the regulation of protein stability and localization.

FCHSD1 is involved in a wide range of physiological processes in the nervous system, including cell survival, growth, and differentiation. It has been shown to play a role in the regulation of neuronal excitability, synaptic plasticity, and neurotransmitter release.

FCHSD1 has also been shown to be a potential drug target. Its unique structure and the involvement in various physiological processes make it an attractive target for small molecules. Additionally, its expression is highly dependent on various cellular signaling pathways, which makes it a potential target for drugs that can modulate these pathways.

Drug Development

Several small molecules have been shown to interact with FCHSD1 and to display potential as a drug. One of the most promising compounds is a small molecule called W-1, which is a potent inhibitor of FCHSD1-mediated signaling pathways.

W-1 was synthesized using a series of libraries of phthalonitrile compounds, and its binding to FCHSD1 was confirmed using a variety of techniques, including biochemical, cellular, and in vitro assays. W-1 has been shown to block the effects of FCHSD1 on neurotransmitter release, cell survival, and neuronal excitability.

Another promising compound is a peptide called P1, which is derived from the N-terminus of FCHSD1. P1 has been shown to have similar effects to W-1, including inhibiting FCHSD1-mediated signaling pathways and modulating neurotransmitter release.

FCHSD1 has also been shown to interact with several other small molecules, including inhibitors of protein phosphateases, modulators of ion channels, and modulators of neurotransmitter receptors. These compounds have the potential to modulate FCHSD1's function and activity, making them potential drug targets.

Conclusion

FCHSD1 is a protein that is involved in various physiological processes in the nervous system and has the potential as a drug target. Its unique structure and the involvement in a wide range of physiological processes make it an attractive target for small molecules. Further research is needed to fully understand the function and potential of FCHSD1 as a drug target.

Protein Name: FCH And Double SH3 Domains 1

Functions: Promotes actin polymerization mediated by SNX9 and WASL

The "FCHSD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FCHSD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FCHSD2 | FCMR | FCN1 | FCN2 | FCN3 | FCRL1 | FCRL2 | FCRL3 | FCRL4 | FCRL5 | FCRL6 | FCRLA | FCRLB | FCSK | FDCSP | FDFT1 | FDPS | FDPSP2 | FDPSP4 | FDPSP5 | FDPSP6 | FDPSP7 | FDX1 | FDX2 | FDXACB1 | FDXR | FECH | FEM1A | FEM1AP4 | FEM1B | FEM1C | FEN1 | FENDRR | FER | FER1L4 | FER1L5 | FER1L6 | FER1L6-AS1 | FER1L6-AS2 | FERD3L | FERMT1 | FERMT2 | FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2